SAN DIEGO, Jan. 28 /PRNewswire-FirstCall/ -- Sequenom, Inc. (Nasdaq: SQNM) today announced that Dr. Wolfgang Holzgreve has joined the company's Clinical Advisory Board. Dr. Holzgreve currently serves as Director and Chairman of the Board of Directors at the University Hospital Freiburg, Germany.
"We are very pleased to welcome Wolfgang to our Clinical Advisory Board," said Dr. Allan Bombard, chief medical officer at Sequenom. "Adding Wolfgang as an active member to our renowned group of advisors will considerably expand our noninvasive prenatal diagnostic experience - an important step as we ramp up our global clinical activities. Additionally, in conjunction with Dr. Yves Ville, who joined in December 2009, we have added an important international perspective to our board. Wolfgang's research and expertise in circulating cell free fetal nucleic acids will be critical as we continue to make progress in executing our prenatal diagnostics strategy."
Dr. Holzgreve graduated from the School of Medicine, the Westfalische Wilhelms-University, Munster, Germany in 1975. In 1976, he earned the degree of Master of Science in Health and Medical Sciences at the University of California, Berkeley. From 1976 to 1978, he studied at the School of Medicine in Munster, Germany, and finished his residency in Obstetrics and Gynecology, Department of Obstetrics and Gynecology, University of Munster, in 1982. Between 1982 and 1984, he completed a Fellowship of the German Research Foundation in Reproductive Genetics, at the Department of Obstetrics and Gynecology and Reproductive Sciences at the University of California, San Francisco, USA. Dr. Holzgreve was Board Certified in Clinical Genetics and Obstetrics and Gynecology in 1985.
By 1991, he had risen to the rank of Professor of Obstetrics and Gynecology, Geschaftsf. Oberarzt, Department of Obstetrics and Gynecology, University of Munster, Germany. In August 1995, he moved to Switzerland to take up his appointment as Chairman of the Department and Chief of Service at the Department of Obstetrics and Gynecology, University of Basel, from where he transitioned to his current position at Freiburg in 2009.
Dr. Wolfgang Holzgreve joins the existing members of the Clinical Advisory Board who are Dr. Frank Chervenak, Dr. Arnold Cohen, Dr. W. Allen Hogge, Dr. Dennis Lo, Dr. Lee Shulman, Dr. Yves Ville, and Dr. Allan Bombard.
Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostics markets. The company was founded in 1994 and is headquartered in San Diego, California. Sequenom maintains a Web site at http://www.sequenom.com to which Sequenom regularly posts copies of its press releases as well as additional information about Sequenom. Interested persons can subscribe on the Sequenom Web site to email alerts or RSS feeds that are sent automatically when Sequenom issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the Web site.
SEQUENOM® is a registered trademark of Sequenom, Inc.
Except for the historical information contained herein, the matters set forth in this press release, including statements regarding the Company's ramp up of global clinical activities and progress in executing its prenatal diagnostics strategy are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with the Company's financial position, its ability to position itself for product launches and growth and develop and commercialize new technologies and products, particularly new technologies such as noninvasive prenatal diagnostics and laboratory developed tests, reliance upon the collaborative efforts of other parties, the Company's ability to manage its existing cash resources or raise additional cash resources, competition, intellectual property protection and intellectual property rights of others, government regulation particularly with respect to diagnostic products and laboratory developed tests, obtaining or maintaining regulatory approvals, litigation, and other risks detailed from time to time in the Company's Annual Report on Form 10-K for the year ended December 31, 2008 and other documents subsequently filed with or furnished to the Securities and Exchange Commission. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.
SOURCE Sequenom, Inc.
|SOURCE Sequenom, Inc.|
Copyright©2010 PR Newswire.
All rights reserved